Intron 1 polymorphism, mutation and the protein expression of epidermal growth factor receptor in relation to the gefitinib sensitivity of Korean lung cancer patients

Korean Journal of Pathology

Volumn 43, Issue 6, 2009, Pages 509-516

  Kim, Mi Jin ^a   Shin, Kyeong Cheol ^a   Lee, Kwan Ho ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Cancer; Epidermal growth factor; Gefitinib; Genetic; Lung; Mutation; Polymorphism; Receptor

Indexed keywords

EID: 77951169870     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2009.43.6.509     Document Type: Article

References (29)

1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
3. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of phase I trial. J Clin Oncol 2002; 20: 2240-50.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003; 21: 2237-46.
5. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer (NSCLC). J Cilin Oncol 2004; 22: 1103-9.
6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from never smokers and are associated with sensitivity of tumor to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-11.
7. Han SH, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 1-9.
8. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195-203.
9. Henrion D, Amant C, Benessiano J, et al. Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro. J Vasc Res 1998; 35: 356-62.
10. Tidow N, Bocker A, Achmidt H, et al. Distinct amplification of an untranslated regulatory sequence in the EGFR gene contributes to early steps in breast cancer development. Cancer Res 2003; 63: 1172-8.
11. Buerger H, Packeisen J, Boecker A, et al. Allelic length of a CA dinucleotide repeat in EGFR gene correlates with the frequency of amplification of this sequence-first results of an interethnic breast cancer study. J Pathol 2004; 203: 545-50.
12. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron I polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64: 9139-43.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guideline to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
14. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.
15. Lee SJ, Kim KM, Chae MH, et al. No association between dinucleotide repeat polymorphism in intron 1 of the epidermal growth factor receptor gene EGFR and risk of lung cancer. Cancer Genet Cytogenet 2007; 172: 29-32.
16. Han SW, Jeon YK, Lee KH, et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefinitib responsiveness in non-small cell lung cancer. Pharmacogenet Genomics 2007; 17: 313-9.
17. Liu W, Innocenti F, Chen P, Das S, Cook EH, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003; 9: 1009-12.
18. Nie Q, Wang Z, Zhang GC, et al. The epidermal growth factor receptor intron 1 (CA) microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with gefitinib. Eur J Pharmacol 2007; 10: 1-7.
19. Sueoka-Aragane N, Imai K, Komya K, et al. Exon 19 of EGFR mutation in relation to CA-repeat polymorphism in intron 1. Cancer Sci 2008; 99: 1180-7.
20. Buerger H, Gebhardt F, Schmidt H, et al. Length and loss of heterozygosityo f an intron 1 polymorphic sequence of EGFR is related to cytogenetic alteration and epithelial growth factor receptor expression. Cancer Res 2000; 60: 854-7.
21. Nomura M, Shigematsu H, Li Lin, et al. Polymorphism, mutations and amplification of the EGFR gene in non-small cell lung cancers. PLoS Medicine 2007; 4: 715-27.
22. Etienne-grimaldi MC, Pereira S, Magne N, et al. Analysis of the dinucleotide repeat polymorphism in the EGFR gene in head and neck cancer patients. Ann Oncol 2005; 16: 934-41.
23. Cappuzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-55.
24. Prudkin L, Wistuba II. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann Diag Pathol 2006; 10: 306-15.
25. Sone T, Kasahara K, Kimura H, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 2007; 109: 1836-44.
26. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erotinib. PLoS Med 2005; 2: e17.
27. Hirsch FR, Varelia-Garcia M, Bunn Jr PA, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-807.
28. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274: 13176-80.
29. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor expression for response to gefitinib ("Irresa", ZD1839) in non-small-cell lung cancer. Br J Cancer 2004; 91: 208-12.